Cargando…
MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer
Epithelial-mesenchymal transition (EMT) accompanying loss of E-cadherin is important for invasiveness and metastasis of bladder cancer. MicroRNAs (miRs) had been associated with cancer progression and differentiation in several cancers. Our goal is to find out the specific miR which modulates EMT in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042001/ https://www.ncbi.nlm.nih.gov/pubmed/27058893 http://dx.doi.org/10.18632/oncotarget.8557 |
_version_ | 1782456527184986112 |
---|---|
author | Wu, Chia-Lun Ho, Jar-Yi Chou, Sheng-Chieh Yu, Dah-Shyong |
author_facet | Wu, Chia-Lun Ho, Jar-Yi Chou, Sheng-Chieh Yu, Dah-Shyong |
author_sort | Wu, Chia-Lun |
collection | PubMed |
description | Epithelial-mesenchymal transition (EMT) accompanying loss of E-cadherin is important for invasiveness and metastasis of bladder cancer. MicroRNAs (miRs) had been associated with cancer progression and differentiation in several cancers. Our goal is to find out the specific miR which modulates EMT in bladder cancer. Real-time quantitative polymerase chain reaction was used to measure the miRs expression in urothelial cell carcinoma (UCC) cell lines. MiR or siRNA mimics was used to regulate miR and mRNA level respectively. Migration and scratch assays were used to determine the migratory ability. Zymography assay was used to confirm the metalloproteinase activity. Western blotting was used to elucidate the mechanism which regulated by specific miR. MiR-429 was highly expressed in low grade UCC cell lines. Exogenous mimic of miR-429 treatment dramatically inhibited the migratory ability of T24 cells. MiR-429 downstream target ZEB1 was decreased, E-cadherin was restored, and β-catenin was contrarily decreased by exogenous mimic of miR-429 treatment in T24 cells. Cell invasive ability was also inhibited by exogenous mimic of miR-429 treatment through inactivating the MMP-2 activity in T24 cells. E-cadherin protein expression level was inhibited by E-cadherin siRNA accompanied with increasing cell migratory ability when compared with control group in low grade TSGH8301 cells. MiR-429 decreased the cell migratory and invasive abilities through reducing ZEB1 and β-catenin, restoring the E-cadherin expression and inactivation of MMP-2 of UCC cells. MiR-429 might be used as a progression marker of bladder cancer. |
format | Online Article Text |
id | pubmed-5042001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-50420012016-10-10 MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer Wu, Chia-Lun Ho, Jar-Yi Chou, Sheng-Chieh Yu, Dah-Shyong Oncotarget Research Paper Epithelial-mesenchymal transition (EMT) accompanying loss of E-cadherin is important for invasiveness and metastasis of bladder cancer. MicroRNAs (miRs) had been associated with cancer progression and differentiation in several cancers. Our goal is to find out the specific miR which modulates EMT in bladder cancer. Real-time quantitative polymerase chain reaction was used to measure the miRs expression in urothelial cell carcinoma (UCC) cell lines. MiR or siRNA mimics was used to regulate miR and mRNA level respectively. Migration and scratch assays were used to determine the migratory ability. Zymography assay was used to confirm the metalloproteinase activity. Western blotting was used to elucidate the mechanism which regulated by specific miR. MiR-429 was highly expressed in low grade UCC cell lines. Exogenous mimic of miR-429 treatment dramatically inhibited the migratory ability of T24 cells. MiR-429 downstream target ZEB1 was decreased, E-cadherin was restored, and β-catenin was contrarily decreased by exogenous mimic of miR-429 treatment in T24 cells. Cell invasive ability was also inhibited by exogenous mimic of miR-429 treatment through inactivating the MMP-2 activity in T24 cells. E-cadherin protein expression level was inhibited by E-cadherin siRNA accompanied with increasing cell migratory ability when compared with control group in low grade TSGH8301 cells. MiR-429 decreased the cell migratory and invasive abilities through reducing ZEB1 and β-catenin, restoring the E-cadherin expression and inactivation of MMP-2 of UCC cells. MiR-429 might be used as a progression marker of bladder cancer. Impact Journals LLC 2016-04-02 /pmc/articles/PMC5042001/ /pubmed/27058893 http://dx.doi.org/10.18632/oncotarget.8557 Text en Copyright: © 2016 Wu et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Wu, Chia-Lun Ho, Jar-Yi Chou, Sheng-Chieh Yu, Dah-Shyong MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer |
title | MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer |
title_full | MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer |
title_fullStr | MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer |
title_full_unstemmed | MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer |
title_short | MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer |
title_sort | mir-429 reverses epithelial-mesenchymal transition by restoring e-cadherin expression in bladder cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042001/ https://www.ncbi.nlm.nih.gov/pubmed/27058893 http://dx.doi.org/10.18632/oncotarget.8557 |
work_keys_str_mv | AT wuchialun mir429reversesepithelialmesenchymaltransitionbyrestoringecadherinexpressioninbladdercancer AT hojaryi mir429reversesepithelialmesenchymaltransitionbyrestoringecadherinexpressioninbladdercancer AT choushengchieh mir429reversesepithelialmesenchymaltransitionbyrestoringecadherinexpressioninbladdercancer AT yudahshyong mir429reversesepithelialmesenchymaltransitionbyrestoringecadherinexpressioninbladdercancer |